Open AccessAllogeneic blood stem cell transplantation in advanced hematologic cancers
Author(s) -
Donna Przepiorka,
Paolo Anderlini,
Cindy Ippoliti,
Issa F. Khouri,
Thomas Fietz,
Peter F. Thall,
Rakesh Mehra,
Sergío Giralt,
James Gajewski,
Albert Deisseroth,
Karen R. Cleary,
Richard E. Champlin,
Koen van Besien,
Börje S. Andersson,
Martin Körbling
Publication year - 1997
Publication title -
bone marrow transplantation
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 127
eISSN - 1476-5365
pISSN - 0268-3369
DOI - 10.1038/sj.bmt.1700692
Subject(s) - medicine , thiotepa , busulfan , transplantation , surgery , bone marrow , stem cell , cyclophosphamide , filgrastim , hemorrhagic cystitis , gastroenterology , hematopoietic stem cell transplantation , chemotherapy , granulocyte colony stimulating factor , biology , genetics
Allogeneic bone marrow transplantation for advanced hematologic cancer is associated with a high risk of early treatment-related morbidity and mortality. To determine the short-term benefits of allogeneic blood stem cell transplants when compared to bone marrow transplants, we reviewed outcomes of 74 adults with advanced hematologic cancer transplanted from HLA-matched related donors after conditioning with thiotepa, busulfan and cyclophosphamide. There were three cohorts: group 1 received bone marrow transplants with cyclosporine (CsA) and methotrexate (MTX) for GVHD prophylaxis; group 2 received bone marrow transplants with CsA and methylprednisolone (MP); and group 3 received blood stem cells with CsA and MP. All patients received filgrastim post-transplant. Median times (range) to neutrophils > or = 0.5 x 10(9)/l were 17 (8-30), 9 (8-16) and 10 (8-13) days post-transplant, and to platelets > or = 20 x 10(9)/l were 28 (14-100+), 19 (13-100+) and 14 (9-86) days post-transplant for groups 1, 2 and 3, respectively (P < 0.05 only for group 1 vs group 3 for both outcomes). Blood stem cell recipients had the least regimen-related toxicity, fewest early deaths and earliest discharge. There was no significant difference in acute GVHD between the three groups. One hundred and eighty-day survivals (95% CI) were 53% (35-72%), 32% (10-53%), and 68% (49-87%) for groups 1, 2 and 3, respectively (P < 0.05 only for group 2 vs group 3). For allogeneic transplantation, use of blood stem cell grafts has substantial advantages over marrow grafts.